SCHEMBL23005169

SCHEMBL23005169

O=CN(c1ncc(NC(=O)CCl)cc1Cl)[C@@H](CCC(=O)O)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 6/20 0.39
TRPV1 Q8NER1 1/20 0.34
MAPT P10636 2/20 0.33
KMT2A Q03164 2/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
FOLH1 Q04609 1/20 0.33
MTHFD1 P11586 1/20 0.32
MTHFD2 P13995 1/20 0.32
HIF1A Q16665 2/20 0.31
GSTO1 P78417 2/20 0.31
ALDH1A1 P00352 3/20 0.31
HTT P42858 3/20 0.31
MITF O75030 2/20 0.31
POLB P06746 1/20 0.31
MAPK1 P28482 1/20 0.31
RORC P51449 1/20 0.31
SMN1; SMN2 Q16637 2/20 0.30
L3MBTL1 Q9Y468 1/20 0.30
NPC1 O15118 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23005244 0.89 FPR2 (0.38) FPR2TRPV1MAPTKMT2AKDM4E
SCHEMBL23005174 0.89 FPR2 (0.38) FPR2MAPTKMT2AKDM4EMEN1
SCHEMBL23005141 0.86 FPR2 (0.40) FPR2MAPTKMT2AKDM4EMEN1
SCHEMBL23005116 0.81 FPR2 (0.31) FPR2
SCHEMBL21494699 0.81 FPR2 (0.65) FPR2MTHFD1MTHFD2
SCHEMBL23005194 0.78 GAA (0.35) MAPTKMT2AMEN1ALDH1A1HTT
SCHEMBL23005115 0.77 FPR2 (0.64) FPR2MTHFD1MTHFD2
SCHEMBL23005136 0.77 GAA (0.34) MAPTKMT2AMEN1ALDH1A1HTT
SCHEMBL23005242 0.71 RORC (0.38) FPR2MTHFD1MTHFD2RORC
SCHEMBL21494665 0.71 FPR2 (0.64) FPR2KDM4EFOLH1MTHFD1MTHFD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3781554-B1 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY THOMAS HELLEDAYS STIFTELSE FOER MEDICINSK FORSKNING (SE) 2023-06-28 EP disclosed
US-20210052587-A1 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY MEDICINSK FORSKNING (SE) 2021-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210052587-A1 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY IL2, THPO, IL6 FPR2 435/4885TRPV1 2763/4885MAPT 2335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.